Literature DB >> 30509704

Research advances in pathogenesis and prophylactic measures of acute high altitude illness.

Yunhong Li1, Yujing Zhang1, Ying Zhang2.   

Abstract

After ascent to high altitude (≥2500 m), the inability of the human body to adapt to the hypobaric and hypoxia environment can induce tissue hypoxia, then a series of high altitude illnesses including acute mountain sickness (AMS), high altitude pulmonary edema (HAPE), and high altitude cerebral edema (HACE) would develop. Symptoms of AMS include headache, dizziness, nausea, and vomiting; HAPE is characterized by orthopnea, breathlessness at rest, cough, pink frothy sputum, and results in obvious pulmonary edema that poses significant harm to people; HACE is characterized by ataxia and decreased consciousness, leading to coma and brain herniation which would be fatal if not treated promptly. This review article provides a current understanding of the pathophysiology of these three forms of high altitude illness and elaborates the current prevention and treatment measures of these diseases.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Acute high-altitude illness; Acute mountain sickness; High altitude pulmonary edema; High-altitude cerebral edema; Prophylactic measures

Mesh:

Substances:

Year:  2018        PMID: 30509704     DOI: 10.1016/j.rmed.2018.11.004

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  12 in total

Review 1.  Sestrin2 as a gatekeeper of cellular homeostasis: Physiological effects for the regulation of hypoxia-related diseases.

Authors:  Cunyao Pan; Zhaoli Chen; Chao Li; Tie Han; Hui Liu; Xinxing Wang
Journal:  J Cell Mol Med       Date:  2021-05-04       Impact factor: 5.310

2.  The multiple organs insult and compensation mechanism in mice exposed to hypobaric hypoxia.

Authors:  Ning Li; Qiuyue Li; Jinrong Bai; Ke Chen; Hailing Yang; Wenxiang Wang; Fangfang Fan; Yi Zhang; Xianli Meng; Tingting Kuang; Gang Fan
Journal:  Cell Stress Chaperones       Date:  2020-05-19       Impact factor: 3.667

3.  HSPA1A gene polymorphism rs1008438 is associated with susceptibility to acute mountain sickness in Han Chinese individuals.

Authors:  Zhicheng Liu; Hong Chen; Ting Xu; Xiaomei Wang; Chunyan Yao
Journal:  Mol Genet Genomic Med       Date:  2020-06-01       Impact factor: 2.183

4.  High-altitude pulmonary edema.

Authors:  Peter Woods; Joe Alcock
Journal:  Evol Med Public Health       Date:  2021-01-06

5.  High Altitude Pulmonary Edema in a Healthy Pediatric Patient Traveling from Denver to Breckenridge.

Authors:  Matthew Adamo; Kayla E Prokopakis; Todd Bolotin
Journal:  Open Access Emerg Med       Date:  2022-01-04

6.  Association Between the Polymorphism of Steroid Hormone Metabolism Genes and High-Altitude Pulmonary Edema in the Chinese Han Population.

Authors:  Hui Gao; Jin Xu; Qiang Ma; Feng Tang; Qin Ga; Yuhong Li; Wei Guan; Ri-Li Ge; Ying-Zhong Yang
Journal:  Int J Gen Med       Date:  2022-01-20

7.  Compound Danshen Dripping Pill inhibits high altitude-induced hypoxic damage by suppressing oxidative stress and inflammatory responses.

Authors:  Yunhui Hu; Jia Sun; Tongxing Wang; Hairong Wang; Chunlai Zhao; Wenjia Wang; Kaijing Yan; Xijun Yan; He Sun
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

8.  [Betelnut polyphenols provide protection against high-altitude hypoxia in rats].

Authors:  Y Huo; A Zhao; J Song; J Li; R Wang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-05-20

9.  Prophylaxis of ibuprofen in acute mountain sickness: A protocol for systematic review and meta-analysis.

Authors:  Hai Yi; Kuiying Wang; Xinyu Gan; Li Li; Qian Zhang; Jiao Xiang; Xiuwei Yuan; Yugang Zhang; Yonghua Wang
Journal:  Medicine (Baltimore)       Date:  2020-11-13       Impact factor: 1.817

Review 10.  Chinese medicinal plants for the potential management of high-altitude pulmonary oedema and pulmonary hypertension.

Authors:  Tingting Wang; Jun Hou; Wenjing Xiao; Yaolei Zhang; Longfu Zhou; Li Yuan; Xiaoqiang Yin; Xin Chen; Yonghe Hu
Journal:  Pharm Biol       Date:  2020-12       Impact factor: 3.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.